These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556 [TBL] [Abstract][Full Text] [Related]
23. Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK. Ingham SL; Warwick J; Byers H; Lalloo F; Newman WG; Evans DG Clin Genet; 2013 Jul; 84(1):37-42. PubMed ID: 23050611 [TBL] [Abstract][Full Text] [Related]
24. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy. Silvestri V; Rizzolo P; Scarnò M; Chillemi G; Navazio AS; Valentini V; Zelli V; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Pensotti V; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D; Ottini L Eur J Cancer; 2015 Nov; 51(16):2289-95. PubMed ID: 26248686 [TBL] [Abstract][Full Text] [Related]
26. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Osorio A; Pollán M; Pita G; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Preisler-Adams S; Niederacher D; Hofmann W; Gadzicki D; Jakubowska A; Hamann U; Lubinski J; Toloczko-Grabarek A; Cybulski C; Debniak T; Llort G; Yannoukakos D; Díez O; Peissel B; Peterlongo P; Radice P; Heikkinen T; Nevanlinna H; Mai PL; Loud JT; McGuffog L; Antoniou AC; Benitez J; Br J Cancer; 2008 Sep; 99(6):974-7. PubMed ID: 18781154 [TBL] [Abstract][Full Text] [Related]
27. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957 [TBL] [Abstract][Full Text] [Related]
28. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations. Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645 [TBL] [Abstract][Full Text] [Related]
29. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048 [TBL] [Abstract][Full Text] [Related]
31. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Milne RL; Antoniou AC Endocr Relat Cancer; 2016 Oct; 23(10):T69-84. PubMed ID: 27528622 [TBL] [Abstract][Full Text] [Related]
32. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW; Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288 [TBL] [Abstract][Full Text] [Related]
33. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061 [TBL] [Abstract][Full Text] [Related]
34. Are VNTRs co-localizing with breast cancer-associated SNPs? Leclerc M; Neuhausen SL; Schayek H; Laitman Y; Antonis AC; Friedman E Breast Cancer Res Treat; 2018 Feb; 168(1):277-281. PubMed ID: 29168065 [TBL] [Abstract][Full Text] [Related]
36. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694 [TBL] [Abstract][Full Text] [Related]
37. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. Barnes DR; Silvestri V; Leslie G; McGuffog L; Dennis J; Yang X; Adlard J; Agnarsson BA; Ahmed M; Aittomäki K; Andrulis IL; Arason A; Arnold N; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Belotti M; Benitez J; Berthet P; Boonen SE; Borg Å; Bozsik A; Brady AF; Brennan P; Brewer C; Brunet J; Bucalo A; Buys SS; Caldés T; Caligo MA; Campbell I; Cassingham H; Christensen LL; Cini G; Claes KBM; ; ; Cook J; Coppa A; Cortesi L; Damante G; Darder E; Davidson R; de la Hoya M; De Leeneer K; de Putter R; Del Valle J; Diez O; Ding YC; Domchek SM; Donaldson A; Eason J; Eeles R; Engel C; Evans DG; Feliubadaló L; Fostira F; Frone M; Frost D; Gallagher D; Gehrig A; Giraud S; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gregory H; Gross E; Hahnen E; Hamann U; Hansen TVO; Hanson H; Hentschel J; Horvath J; ; ; Izatt L; Izquierdo A; James PA; Janavicius R; Jensen UB; Johannsson OT; John EM; Kramer G; Kroeldrup L; Kruse TA; Lautrup C; Lazaro C; Lesueur F; Lopez-Fernández A; Mai PL; Manoukian S; Matrai Z; Matricardi L; Maxwell KN; Mebirouk N; Meindl A; Montagna M; Monteiro AN; Morrison PJ; Muranen TA; Murray A; Nathanson KL; Neuhausen SL; Nevanlinna H; Nguyen-Dumont T; Niederacher D; Olah E; Olopade OI; Palli D; Parsons MT; Pedersen IS; Peissel B; Perez-Segura P; Peterlongo P; Petersen AH; Pinto P; Porteous ME; Pottinger C; Pujana MA; Radice P; Ramser J; Rantala J; Robson M; Rogers MT; Rønlund K; Rump A; Sánchez de Abajo AM; Shah PD; Sharif S; Side LE; Singer CF; Stadler Z; Steele L; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teulé A; Thull DL; Tischkowitz M; Toland AE; Tommasi S; Toss A; Trainer AH; Tripathi V; Valentini V; van Asperen CJ; Venturelli M; Viel A; Vijai J; Walker L; Wang-Gohrke S; Wappenschmidt B; Whaite A; Zanna I; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC; Ottini L; J Natl Cancer Inst; 2022 Jan; 114(1):109-122. PubMed ID: 34320204 [TBL] [Abstract][Full Text] [Related]
38. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450 [TBL] [Abstract][Full Text] [Related]
39. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Chenevix-Trench G; Milne RL; Antoniou AC; Couch FJ; Easton DF; Goldgar DE; Breast Cancer Res; 2007; 9(2):104. PubMed ID: 17466083 [TBL] [Abstract][Full Text] [Related]
40. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status. Figueiredo JC; Brooks JD; Conti DV; Poynter JN; Teraoka SN; Malone KE; Bernstein L; Lee WD; Duggan DJ; Siniard A; Concannon P; Capanu M; Lynch CF; Olsen JH; Haile RW; Bernstein JL Breast Cancer Res Treat; 2011 Jun; 127(3):819-29. PubMed ID: 21161372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]